TY - JOUR
T1 - On the continuous (R)evolution of antibody-based and CAR T cell therapies in multiple myeloma
T2 - an early 2022 glance into the future
AU - Sunder-Plassmann, Vincent
AU - Aksoy, Osman
AU - Lind, Judith
AU - Pecherstorfer, Martin
AU - Vallet, Sonia
AU - Podar, Klaus
N1 - Funding Information:
This paper was not funded.This investigation was supported by the WST3-F-5031 298/003-2019 (KP) and the Life Science grant LSC18-010 (SV and KP). KP and MP are recipients of a research support grant from Roche Pharmaceuticals.
Funding Information:
SV received speaker’s honoraria from Bristol Myers Squibb, MSD, Pfizer, and consultancy fees from Roche, Eusa, MSD, and Merck; KP has received speaker’s honoraria from Celgene, Amgen Inc. and Janssen Pharmaceuticals, consultancy fees from Celgene, Takeda and Janssen Pharmaceuticals, and research support from Roche Pharmaceuticals. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. The remaining authors declare no conflict of interest.
Publisher Copyright:
© 2022 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2022
Y1 - 2022
N2 - INTRODUCTION: The pace at which the identification of novel therapeutic targets has led to the approval of multiple myeloma (MM) agents during the last two decades is nothing more than spectacular. Nevertheless, MM remains an incurable disease. Therefore, there is an urgent need for additional, innovative therapeutics. Immune dysfunction and the tumor-permissive immune bone marrow microenvironment represent hallmarks of MM pathophysiology. Naked monoclonal antibodies directed against SLAMF7 and CD38 already constitute backbones of today's MM therapy. Novel immunotherapeutic modalities including antibody-drug-conjugates (ADC), bispecific antibodies (BsAb), and chimeric-antigen-receptor T cells are on the way to once more revolutionize future MM therapy.AREAS COVERED: The present review article summarizes the most recent results on MM immunotherapies presented at the 2021 Annual Meeting of the American Society of Hematology; and throws a glance on ongoing preclinical and clinical efforts aiming at further increasing their efficacy, while reducing their toxicity.EXPERT OPINION: With the approvals of the first-in-class BCMA-targeting ADC (belantamab mafodotin) and two BCMA-targeting CAR T cell products (Ide-cel, Cilta-cel); and the approval of the first-in-class BCMAxCD3 BsAb immediately pending, the era of modern next-generation immunotherapies in MM is continuously evolving. Long-term disease-free survival and potential cure of MM are finally within reach.
AB - INTRODUCTION: The pace at which the identification of novel therapeutic targets has led to the approval of multiple myeloma (MM) agents during the last two decades is nothing more than spectacular. Nevertheless, MM remains an incurable disease. Therefore, there is an urgent need for additional, innovative therapeutics. Immune dysfunction and the tumor-permissive immune bone marrow microenvironment represent hallmarks of MM pathophysiology. Naked monoclonal antibodies directed against SLAMF7 and CD38 already constitute backbones of today's MM therapy. Novel immunotherapeutic modalities including antibody-drug-conjugates (ADC), bispecific antibodies (BsAb), and chimeric-antigen-receptor T cells are on the way to once more revolutionize future MM therapy.AREAS COVERED: The present review article summarizes the most recent results on MM immunotherapies presented at the 2021 Annual Meeting of the American Society of Hematology; and throws a glance on ongoing preclinical and clinical efforts aiming at further increasing their efficacy, while reducing their toxicity.EXPERT OPINION: With the approvals of the first-in-class BCMA-targeting ADC (belantamab mafodotin) and two BCMA-targeting CAR T cell products (Ide-cel, Cilta-cel); and the approval of the first-in-class BCMAxCD3 BsAb immediately pending, the era of modern next-generation immunotherapies in MM is continuously evolving. Long-term disease-free survival and potential cure of MM are finally within reach.
KW - Car T-cells
KW - Multiple myeloma
KW - antibody-drug-conjugates
KW - bispecific antibodies
KW - monoclonal antibodies
KW - B-Cell Maturation Antigen
KW - Multiple Myeloma/therapy
KW - Receptors, Chimeric Antigen/therapeutic use
KW - Immunotherapy, Adoptive/methods
KW - Humans
KW - Tumor Microenvironment
KW - Antibodies, Bispecific/therapeutic use
UR - http://www.scopus.com/inward/record.url?scp=85136925051&partnerID=8YFLogxK
U2 - 10.1080/14656566.2022.2101362
DO - 10.1080/14656566.2022.2101362
M3 - Review article
C2 - 35829636
SN - 1465-6566
VL - 23
SP - 1425
EP - 1444
JO - Expert Opinion on Pharmacotherapy
JF - Expert Opinion on Pharmacotherapy
IS - 12
ER -